Rhesuman 300mcg Injection belongs to the class of medications called ‘immunising agents’ used to prevent rhesus disease. Rhesus factor type D (RhD) is a special characteristic of human red blood cells. People who carry the RhD factor are called RhD positive, and those who don’t carry the RhD factor are called RhD negative. Rhesus disease occurs if there are mixed blood types of RhD-positive and RhD-negative. It can happen in the case of a pregnant woman when the mother is RhD negative, and the baby is RhD positive and people who have received mismatched transfusion ((RhD negative child or adult who have accidentally received RhD positive blood).

Rhesuman 300mcg Injection contains ‘Anti-D (Rh) immunoglobulin’, an immunising agent. Immunoglobulins or antibodies are essential to the immune response and help by protecting against viruses to prevent infection. Rhesuman 300mcg Injection works by neutralising the RhD-positive antigens that may have entered an RhD-negative person’s blood. Rhesuman 300mcg Injection is not recommended for use in positive RhD patients and individuals already immunised to RhD antigen.

Rhesuman 300mcg Injection is available as an injection and given by a healthcare professional. Rhesuman 300mcg Injection may cause side effects such as pain and tenderness at the injection site. These side effects are usually mild and temporary. However, if any of these side effects persist or worsen, inform your doctor immediately.

It is not recommended to take Rhesuman 300mcg Injection if you are allergic to human immunoglobulin or other ingredients. Before taking Rhesuman 300mcg Injection, inform your doctor if you had vaccination recently within the last 2 to 4 weeks, have blood clotting problems, or have thrombocytopenia (decreased number of platelets in the blood). Rhesuman 300mcg Injection is intended for use in pregnant women and is probably safe for breastfeeding mothers. Rhesuman 300mcg Injection may not interact with alcohol and may not affect your driving ability.

Rhesuman 300mcg Injection contains 'Anti-D (Rh) immunoglobulin', which is used to prevent rhesus disease. Rhesuman 300mcg Injection is recommended for use in RhD-negative women who are carrying, just delivered, or have lost an RhD-positive baby. It is also recommended for RhD-negative women carrying RhD-positive babies if the pregnant woman has a severely complicated pregnancy, if the baby's RhD-positive blood passes into the mother's blood circulation, if the doctor needs to perform testing methods to identify fetal deformities, if the doctor is trying to move the baby from outside, or if the mother experiences abdominal trauma (injury to gut or stomach). Rhesuman 300mcg Injection is also administered during the third trimester of pregnancy if the pregnant woman's blood type is RhD negative. This is called routine antenatal anti-D prophylaxis. Rhesuman 300mcg Injection is also given to people who had mismatched transfusions (RhD-negative child or adult who have accidentally received RhD-positive blood).

• Pain at the injection site
• Tenderness
• Fever 
• Headache

Rhesuman 300mcg Injection is given to prevent rhesus disease in RhD-negative women after delivery of an RhD-positive child, so it is always given to the mother and not to the newborn. Rhesuman 300mcg Injection is not recommended for use in RhD positive persons and individuals already immunized to RhD antigen. Rhesuman 300mcg Injection may cause allergic reactions such as a sudden drop in blood pressure or shock, even if you have previously received human immunoglobulin and tolerated it well. In such cases, inform your doctor immediately. After a mismatched transfusion, the doctor may give you this medicine in large amounts in people given the Rhesuman 300mcg Injection. In such cases, the doctor may monitor closely and do blood tests as there is a chance of hemolytic reaction (destruction of foreign RhD-positive red blood cells).

Drug-Drug Interactions: Rhesuman 300mcg Injection may interact with the vaccine taken against measles, mumps, and rubella (MMR) and the vaccine taken against chickenpox (varicella), making them less effective. So, these vaccines should be delayed for at least three months after taking Rhesuman 300mcg Injection.

Drug-Food Interactions: No interactions found.

Drug-Disease Interactions: Rhesuman 300mcg Injection should be used with caution in people with clotting disorders, thrombocytopenia (reduced number of platelets) and with immunoglobulin A (IgA) deficiency (IgA is a type of antibody that protects against infections).

• VARICELLA (LIVE ATTENUATED)
• MMR VACCINE

• Undergo blood tests as recommended by the doctor during the pregnancy. It helps to determine whether you are Rh-positive or negative.
• Consume a healthy diet.
• Avoid alcohol and quit smoking during pregnancy, as it may lead to complications.
• Take your medicines regularly as prescribed by your doctor.

• Inform your doctor if you have recently been vaccinated or planned to get vaccinated, especially MMR and varicella, as Rhesuman 300mcg Injection can make these vaccines less effective. Also, do not take live vaccines within three months after taking Rhesuman 300mcg Injection.
• The patient should be observed for 20 minutes after the injection to exclude any allergic reaction development.

Rhesus disease: Rhesus factor type D (RhD) is a special characteristic of human red blood cells. People who carry the RhD factor are called RhD positive, and those who don’t carry the RhD factor are called RhD negative. Rhesus disease occurs if there is a mix of blood types of RhD-positive and RhD-negative. It can occur in the case of a pregnant woman when the mother is RhD negative, and the baby is RhD positive and people who have received mismatched transfusion ((RhD negative child or adult who have accidentally received RhD positive blood). Symptoms may include yellowing of the skin and whites of the eyes (jaundice), pale complexion or pallor, increased heart rate, fast breathing, decreased energy levels and a large abdomen. If this condition is left untreated, it may lead to stillbirth, brain damage, blindness or learning difficulties.